New drug targets liver fat in MASH: early trial begins
NCT ID NCT06947304
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 25 times
Summary
This early-phase study tests a drug called miricorilant in 8 adults with MASH, a fatty liver disease linked to metabolism. The goal is to see if the drug can lower fat production in the liver over 6 weeks. Participants take the drug and have imaging and blood tests to measure changes. This is a small, open-label trial to gather initial safety and effectiveness data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Missouri
RECRUITINGColumbia, Missouri, 65211, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.